Dravet Syndrome Diagnosis and the Impact of Genetic Testing in Epilepsy

In “Dravet Syndrome Diagnosis and the Impact of Genetic Testing in Epilepsy,” our panel explores the growing role of genetic testing in confirming a diagnosis of Dravet syndrome and the clinical implications of identifying pathogenic SCN1A variants. Expert faculty discuss how genetic testing has evolved from a specialized diagnostic tool to an essential component of the epilepsy evaluation, particularly for patients with unexplained seizures and developmental concerns. The conversation highlights how genetic testing can provide diagnostic clarity even after a single seizure event and may help clinicians identify patients at risk for Dravet syndrome before the full clinical phenotype emerges.

The panel reviews the complexities of interpreting genetic test results, emphasizing that not every SCN1A variant results in Dravet syndrome and that clinical context remains critical when establishing a diagnosis. Faculty discuss how earlier genetic confirmation can influence treatment selection, including the avoidance of sodium channel–blocking antiseizure medications that may worsen outcomes in patients with Dravet syndrome. The discussion also examines how genetic information can help clinicians move from a reactive to a proactive approach to care by enabling earlier counseling, treatment planning, and anticipatory management.

In addition, the panel reviews the short- and long-term consequences of delayed diagnosis, including seizure burden, developmental outcomes, and the increased risk of sudden unexpected death in epilepsy (SUDEP). Expert faculty also discuss the importance of seizure action plans, rescue medications, and family education, highlighting how an early genetic diagnosis can improve both medical management and long-term care planning for patients with Dravet syndrome.

Our next episode, “Genetic Testing Approaches in Dravet Syndrome,” expert faculty will review the strengths and limitations of current genetic testing strategies, including epilepsy gene panels, whole-exome sequencing, and whole-genome sequencing. The panel discusses practical factors that influence test selection, the evolving role of comprehensive genomic testing, and how advances in genetic technologies are improving the diagnosis of Dravet syndrome and other genetic epilepsies.